Business
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern’s retirement from the Board. \"On behalf of the Esperion team and our directors, I am very pleased to welcome Stephen to the Esperion Board. Stephen’s extensive experience as a senior business and legal executive for multiple public life science organizations will be a great asset for Esperion as we continue to commercialize our medicines and grow our pipeline,” said Sheldon Koenig, president and chief executive officer of Esperion. “We look forward to Stephen’s guidance as we also continue to drive toward the readout of our unprecedented CLEAR Outcomes trial in the first quarter of 2023. I also want to thank Dr. McGovern for his eight years of service on our Board and his significant contributions to Esperion’s journey.” \"I believe in Esperion’s vision and its mission to deliver innovative medicines to patients in need. I look forward to working with this team in the advancement of the ongoing commercialization of its approved products, the further development of the pre-clinical ACL inhibitor and oral PCSK9 inhibitor pipeline programs, and in preparation for the CLEAR Outcomes study topline results,\" said Mr. Rocamboli. Mr. Rocamboli is currently Chief Executive Officer of Perla Therapeutics, Inc., a company located in the greater Boston area, developing first-in-class antibody therapeutics for the treatment of cancer. Previously, he served as Chief Business Officer, General Counsel and Corporate Secretary of Candel Therapeutics, an immuno-oncology company based in Needham, Massachusetts, between April 2015 and May 2020 (CNDL). Between 2010 and April 2015, Mr. Rocamboli served as general partner of Integrin Partners, LLC, a consulting firm providing corporate development, strategic transaction advisory and general counsel services to life science companies, investors, and entrepreneurs. Between 2010 and 2012, Mr. Rocamboli also served as partner of Beijing International Group, an international affiliate of Integrin Partners. Between 2014 and 2015, he also served as Special Counsel to Wyrick Robbins Yates & Ponton, LLP, focusing on li...